Recent advances in understanding and treating nephrotic syndrome

F1000Research

Volumn 6, Issue , 2017, Pages

  Saleem, Moin ^a   Bierzynska, Agnieszka ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Focal segmental glomerulosclerosis; FSGS; Idiopathic nephrotic syndrome; MCNS; Minimal change nephrotic syndrome; SRNS

Indexed keywords

ABATACEPT; B7 1 ANTIBODY; BIOLOGICAL MARKER; CD20 ANTIBODY; GALACTOSE; HEMOPEXIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 13; MONOCLONAL ANTIBODY; RECOMBINANT HEMOPEXIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

AGE DISTRIBUTION; CIRCULATING FACTOR DISEASE; CLINICAL TRIAL (TOPIC); CONGENITAL NEPHROTIC SYNDROME; DISEASE CLASSIFICATION; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; GENE SEQUENCE; GENETIC DISORDER; GLOMERULONEPHRITIS; HERITABILITY; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; MINIMAL CHANGE NEPHROTIC SYNDROME; NEPHROTIC SYNDROME; PATHOGENESIS; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PODOCYTE; REVIEW; SIGNAL TRANSDUCTION;

EID: 85013814227     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.10165.1     Document Type: Review

References (42)

1. Bierzynska A McCarthy HJ Soderquest K: Genomic and clinical profiling of a national Nephrotic Syndrome cohort advocates a precision medicine approach to disease management. Kidney Int. 2017; pii: S0085-2538(16)30612-3, in press. 28117080 10.1016/j.kint.2016.10.013
2. Gee HY Ashraf S Wan X: Mutations in EMP2 cause childhood-onset nephrotic syndrome. Am J Hum Genet. 2014;94(6):884-90. 24814193 10.1016/j.ajhg.2014.04.010 4121470 F1000 Recommendation
3. Gee HY Zhang F Ashraf S: KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. J Clin Invest. 2015;125(6):2375-84. 25961457 10.1172/JCI79504 4497755 F1000 Recommendation
4. Hinkes BG Mucha B Vlangos CN: Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes ( NPHS1, NPHS2, WT1, and LAMB2). Pediatrics. 2007;119(4):e907-19. 17371932 10.1542/peds.2006-2164
5. Sadowski CE Lovric S Ashraf S: A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26(6):1279-89. 25349199 10.1681/ASN.2014050489 4446877 F1000 Recommendation
6. Kaplan JM Kim SH North KN: Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet. 2000;24(3):251-6. 10700177 10.1038/73456 F1000 Recommendation
7. McCarthy HJ Bierzynska A Wherlock M: Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2013;8(4):637-48. 23349334 10.2215/CJN.07200712 3613958
8. Ulinski T: Recurrence of focal segmental glomerulosclerosis after kidney transplantation: strategies and outcome. Curr Opin Organ Transplant. 2010;15(5):628-32. 20733489 10.1097/MOT.0b013e32833dee3a
9. Gallon L Leventhal J Skaro A: Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med. 2012;366(17):1648-9. 22533598 10.1056/NEJMc1202500 F1000 Recommendation
10. van den Berg JG Weening JJ: Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci (Lond). 2004;107(2):125-36. 15157184 10.1042/CS20040095
11. Sinha A Bagga A: Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol. 2013;9(3):154-69. 23338210 10.1038/nrneph.2012.289
12. Liu LL Qin Y Cai JF: Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin Immunol. 2011;139(3):314-20. 21450528 10.1016/j.clim.2011.02.018 F1000 Recommendation
13. Maas RJ Deegens JK Wetzels JF: Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. Nephrol Dial Transplant. 2014;29(12):2207-16. 25416821 10.1093/ndt/gfu355 F1000 Recommendation
14. Pinto J Lacerda G Cameron JS: Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation. 1981;32(2):83-9. 7027555 10.1097/00007890-198108000-00001
15. Artero M Biava C Amend W: Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med. 1992;92(4):375-83. 1558084 10.1016/0002-9343(92)90267-F
16. Sener A Bella AJ Nguan C: Focal segmental glomerular sclerosis in renal transplant recipients: predicting early disease recurrence may prolong allograft function. Clin Transplant. 2009;23(1):96-100. 19200221 10.1111/j.1399-0012.2008.00908.x
17. Ding WY Koziell A McCarthy HJ: Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J Am Soc Nephrol. 2014;25(6):1342-8. 24511128 10.1681/ASN.2013080852 4033379
18. Konigshausen E Sellin L: Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates. Biomed Res Int. 2016;2016:3765608. 27200372 10.1155/2016/3765608 4856884 F1000 Recommendation
19. Coward RJ Foster RR Patton D: Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, Podocin, and CD2 associated protein in cultured human podocytes. J Am Soc Nephrol. 2005;16(3):629-37. 15659563 10.1681/ASN.2004030172
20. Harris JJ McCarthy HJ Ni L: Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1. J Pathol. 2013;229(5):660-71. 23436459 10.1002/path.4149
21. Bitzan M Babayeva S Vasudevan A: TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation. Pediatr Nephrol. 2012;27(12):2217-26. 22538781 10.1007/s00467-012-2163-3
22. Kachurina N Chung CF Benderoff E: Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis. Am J Physiol Renal Physiol. 2016;310(10):F1148-56. 26719363 10.1152/ajprenal.00349.2015 F1000 Recommendation
23. Faul C Donnelly M Merscher-Gomez S: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931-8. 18724379 10.1038/nm.1857 4109287 F1000 Recommendation
24. Jiang L Dasgupta I Hurcombe JA: Levamisole in steroid-sensitive nephrotic syndrome: usefulness in adult patients and laboratory insights into mechanisms of action via direct action on the kidney podocyte. Clin Sci (Lond). 2015;128(12):883-93. 25626449 10.1042/CS20140749 F1000 Recommendation
25. Mathieson PW: Immunomodulatory Drugs and the Podocyte. Podocytopathy. 2014;183:199-206. Reference Source
26. Xing CY Saleem MA Coward RJ: Direct effects of dexamethasone on human podocytes. Kidney Int. 2006;70(6):1038-45. 16837924 10.1038/sj.ki.5001655
27. Fornoni A Sageshima J Wei C: Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46. 21632984 10.1126/scitranslmed.3002231 3719858 F1000 Recommendation
28. Ravani P Ponticelli A Siciliano C: Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int. 2013;84(5):1025-33. 23739238 10.1038/ki.2013.211 3816123
29. Yu CC Fornoni A Weins A: Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369(25):2416-23. 24206430 10.1056/NEJMoa1304572 3951406 F1000 Recommendation
30. Mundel P Greka A: Developing therapeutic 'arrows' with the precision of William Tell: the time has come for targeted therapies in kidney disease. Curr Opin Nephrol Hypertens. 2015;24(4):388-92. 26050127 10.1097/MNH.0000000000000137 4499164 F1000 Recommendation
31. Lek M Karczewski KJ Minikel EV: Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285-91. 27535533 10.1038/nature19057 5018207 F1000 Recommendation
32. Cheung PK Klok PA Baller JF: Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin. Kidney Int. 2000;57(4):1512-20. 10760087 10.1046/j.1523-1755.2000.00996.x
33. Bakker WW van Dael CM Pierik LJ: Altered activity of plasma hemopexin in patients with minimal change disease in relapse. Pediatr Nephrol. 2005;20(10):1410-5. 16079987 10.1007/s00467-005-1936-3
34. Lennon R Singh A Welsh GI: Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. J Am Soc Nephrol. 2008;19(11):2140-9. 18753258 10.1681/ASN.2007080940 2573012 F1000 Recommendation
35. Wei C El Hindi S Li J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952-60. 21804539 10.1038/nm.2411 4089394 F1000 Recommendation
36. Kronbichler A Saleem MA Meijers B: Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View. J Immunol Res. 2016;2016: 2068691. 27504461 10.1155/2016/2068691 4967695
37. Bakr A Shokeir M El-Chenawi F: Tumor necrosis factor-alpha production from mononuclear cells in nephrotic syndrome. Pediatr Nephrol. 2003;18(6):516-20. 12707837 F1000 Recommendation
38. Joy MS Gipson DS Powell L: Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010;55(1):50-60. 19932542 10.1053/j.ajkd.2009.08.019 2804955
39. Kim SH Park SJ Han KH: Pathogenesis of minimal change nephrotic syndrome: an immunological concept. Korean J Pediatr. 2016;59(9):205-11. 27279884 10.3345/kjp.2016.59.5.205 4897155
40. Lai KW Wei CL Tan LK: Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol. 2007;18(5):1476-85. 17429054 10.1681/ASN.2006070710 F1000 Recommendation
41. Savin VJ McCarthy ET Sharma R: Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res. 2008;151(6):288-92. 18514139 10.1016/j.trsl.2008.04.001
42. Sgambat K Banks M Moudgil A: Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2013;28(11):2131-5. 23793883 10.1007/s00467-013-2539-z